Barclays Downgrades Halozyme Therapeutics (HALO) to Equalweight

August 2, 2013 6:58 AM EDT Send to a Friend
Get Alerts HALO Hot Sheet
Price: $9.12 -0.33%

Rating Summary:
    8 Buy, 1 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 14 | New: 40
Trade HALO Now!
Join SI Premium – FREE
Barclays downgraded Halozyme Therapeutics (NASDAQ: HALO) from Overweight to Equalweight with a price target of $8.00 (from $9.00).

For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.

Shares of Halozyme Therapeutics closed at $7.32 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Downgrades

Related Entities

Barclays

Add Your Comment